ClinicalTrials.Veeva

Menu

Short Term Intermittent Fasting and Insulin Resistance (IFAST)

University of Copenhagen logo

University of Copenhagen

Status

Unknown

Conditions

Diabetes Mellitus
Obesity
Non-alcoholic Fatty Liver Disease
Metabolic Syndrome

Treatments

Other: Time control
Behavioral: Intermittent fasting

Study type

Interventional

Funder types

Other

Identifiers

NCT02420054
Intermittent Fasting

Details and patient eligibility

About

The purpose of the study is to determine the effect of intermittent fasting on insulin secretion and insulin sensitivity in skeletal muscle and fat distribution.

Full description

Approximately 250.000 patients are diagnosed with type 2 diabetes (T2DM) in Denmark, and world-wide close to 350 million people suffer from diabetes. T2DM develops in genetically susceptible individuals as a result of excess energy intake and insufficient amount of daily physical activity. The pathophysiology encompasses a mismatch between the insulin secretory capacity and insulin sensitivity, predominantly manifested in skeletal muscle as insulin resistance. T2DM is associated with increased morbidity and mortality.

The disease is triggered by the individual lifestyle, and thereby the potential for prevention and reversal of the disease in its early years after diagnosis is quite large.

One potential way to improve glucose homeostasis is by intermittent fasting, also known as alternate day fasting. Intermittent fasting means switching between eating and fasting, and it is a variation of calorie restriction. Intermittent fasting has been studied in animals. Together with calorie restriction, intermittent fasting is the most efficient way to expand lifespan of many animal species without genetically altering them. A wide range of age related changes are delayed including beneficial effects on hypertension, degenerative brain disease, immune responses, DNA repair capacity and glucose homeostasis. Fat redistribution with fat translocating from between the organs and the liver to the subcutis.

Little is known about intermittent fasting in humans. In 2005 the investigators experimentally tested this concept in young healthy males and found that 15 days of alternating days with fast and food intake increased insulin sensitivity by 16% without any changes in body weight.

The explanation could be oscillations in cellular energy stores. Skeletal muscle contains approximately 80% of the stored glycogen alone by virtue of the muscle mass. The liver has a higher glycogen concentration, but it is much smaller. A single prolonged (>24 hrs) day of fasting may not decrease muscle glycogen, while the decrease in the liver is very fast. A muscle glycogen lowering effect of continued intermittent fasting would be expected, and experimentally indicated.

The intermittent fasting method may appeal to some patients, who do not exercise, and the need for testing this intervention in patients with type 2 diabetes is obvious.

Enrollment

20 estimated patients

Sex

Male

Ages

40 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • BMI 28-35
  • Type 2 diabetes or metabolically healthy
  • Diet or orally administered treatment for type 2 diabetes

Exclusion criteria

  • Regular physical activity
  • Other diseases than type 2 diabetes
  • insulin treatment
  • alcohol abuse

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

20 participants in 2 patient groups

Intermittent fasting
Active Comparator group
Description:
Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
Treatment:
Behavioral: Intermittent fasting
Time control
Active Comparator group
Description:
A time control period.
Treatment:
Other: Time control

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems